Successful conversion from butorphanol nasal spray to buprenorphine/naloxone using a low-dose regimen to assist with opioid tapering in the setting of chronic pain and migraine management in an older adult patient: A case report
Background Butorphanol is marketed as a treatment for migraines; however, evidence suggests that the harms of its use exceed the benefits. The short half-life of butorphanol places patients at high risk for opioid dependence and makes tapering a challenge. Buprenorphine/naloxone has unique pharmacol...
Saved in:
| Main Authors: | , , , |
|---|---|
| 格式: | 图书 |
| 出版: |
Taylor & Francis Group,
2022-12-01T00:00:00Z.
|
| 主题: | |
| 在线阅读: | Connect to this object online. |
| 标签: |
添加标签
没有标签, 成为第一个标记此记录!
|
因特网
Connect to this object online.3rd Floor Main Library
| 索引号: |
A1234.567 |
|---|---|
| 复印件 1 | 可用 |